Inflammation of solar keratoses following systemic 5-fluorouracil

British Journal of Dermatology

Volumn 135, Issue 3, 1996, Pages 478-480

  Bataille, V ^a,c   Cunningham, D ^a   Mansi, J ^b   Mortimer, P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL;

ACTINIC KERATOSIS; AGED; ARTICLE; CANCER; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHOTOSENSITIVITY; PRIORITY JOURNAL;

EID: 0029824367     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb01520.x     Document Type: Article

References (17)

1. Swain SM, Lippman ME, Egan EF et al. Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890-9.
2. Cunningham D, Hill ME, Watson M, Norman AR. Survival after systemic therapy for metastatic colorectal cancer. Lancet 1995; 345: 328-9.
3. Atkins JM. Fluorouracil and palmar-plantar erythrodysesthesia syndrome. Ann intern Med 1985; 102: 419.
4. Falkson G, Schulz EJ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962; 74: 229-36.
5. Omura EF, Torre D. Inflammation of actinic keratoses due to systemic fluorouracil therapy. J Am Med Assoc 1969; 208: 150-1.
6. Omura EF. Skin reaction to systemic 5-FU - a therapeutic bonus. N Engl J Med 1977; 297: 946.
7. Vukelja SJ, Bonner MW, McCollough M, et al. Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. J Am Acad Dermatol 1991; 25: 905-8.
8. Bernstein T. Skin reactions to 5-fluorouracil. N Engl J Med 1977; 297: 337-8.
9. Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989; 111: 688-9.
10. Dudley K, Micetich K, Massa MC. Erythema with features of seborrheic dermatitis and lupus erythematosus associated with systemic 5-fluorouracil. Cutis 1987; 39: 64-6.
11. Reed WP, Morris DM. Maculopapular eruption resulting from systemic administration of 5-fluorouracil. Cutis 1984; 33: 381-2.
12. Lokich J, Bothe A, Fine N, Perri J. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565-8.
13. Pinedo M, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.
14. Wu XP, Dolnick BJ. 5-fluorouracil alters dihydrofolate reductase pre-mRNA splicing as determined by quantitative polymerase chain reaction. Mol Pharmacol 1993; 44: 22-9.
15. Beck A, Etienne MC, Cheradame S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthease in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-22.
16. Rheman I, Quinn AG, Healy E, Rees J. High frequency of loss of heterozygosity in actinic keratoses. a usually benign disease. Lancet 1994; 344: 788-9.
17. Kamb A. Cancer. Sun protection and P53. Nature 1994; 372: 730-1.